Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-25
2006-04-25
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C544S284000, C544S287000
Reexamination Certificate
active
07034033
ABSTRACT:
A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.
REFERENCES:
patent: 3177218 (1965-04-01), Brown
patent: 4128643 (1978-12-01), Merkel et al.
patent: 4211867 (1980-07-01), Rasmussen
patent: 4287341 (1981-09-01), Hess et al.
patent: 4496571 (1985-01-01), Yellin et al.
patent: 4732916 (1988-03-01), Satoh et al.
patent: 4748165 (1988-05-01), Jones et al.
patent: 4874864 (1989-10-01), Schnur et al.
patent: 4948891 (1990-08-01), Schnur et al.
patent: 4948901 (1990-08-01), Schnur et al.
patent: 5086057 (1992-02-01), Sasagawa et al.
patent: 5124328 (1992-06-01), Fisher et al.
patent: 5352704 (1994-10-01), Okuyama et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5637439 (1997-06-01), Kaneko et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5885985 (1999-03-01), Macdonald et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 5962530 (1999-10-01), Engel et al.
patent: 6020349 (2000-02-01), Ankersen et al.
patent: 6030985 (2000-02-01), Gentile et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6060589 (2000-05-01), Stark et al.
patent: 6127343 (2000-10-01), Andersen et al.
patent: 6180603 (2001-01-01), Frey, II
patent: 6225331 (2001-05-01), Cupps et al.
patent: 6297233 (2001-10-01), Stein et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6391878 (2002-05-01), Cupps et al.
patent: 6716840 (2004-04-01), Chu et al.
patent: 2002/0137939 (2002-09-01), Renhowe et al.
patent: 2002/0193595 (2002-12-01), Chu et al.
patent: 2003/0195187 (2003-10-01), Boyce et al.
patent: 2003/0207814 (2003-11-01), Boyce et al.
patent: 2003/0229025 (2003-12-01), Xiao et al.
patent: 31 08 322 (1981-12-01), None
patent: 0343894 (1989-11-01), None
patent: WO 96/24580 (1996-08-01), None
patent: WO 97/19911 (1997-06-01), None
patent: WO 97/41119 (1997-11-01), None
patent: WO 98/07420 (1998-02-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/17191 (2000-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 02/18327 (2002-03-01), None
patent: WO 02/062776 (2002-08-01), None
patent: WO 02/81443 (2002-10-01), None
patent: WO 02/081443 (2002-10-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
See Goodfellow et al. Curr. Top. Med. Chem. 3(8): 855-83, 2003.
Fisher et al. Int. J. Obes. Relat. Metab. Diord. 23, Suppl. I: 54-58, 1999.
Julia, M. et al., “Amidines and guanidines related to congocidine. III. Urea and trazene diamidines,”Bull. Soc. Chim. Fr., No. 1, pp. 376-382, 1968, published by Masson Editeur, Paris, France.
Mountjoy, K. G. et al., “The Cloning of a Family of Genes That Encode the Melanocortin Receptors,”Science, vol. 257, pp. 1248-1251, Aug. 28, 1992.
Lu, D. et al., “Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor,”Nature, vol. 371, pp. 799-802, Oct. 27, 1994.
Huszar, D. et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell, vol. 88, pp. 131-141, Jan. 10, 1997, published by Cell Press.
Ollmann, M. M. et al., “Antagonism of Central melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, vol. 278, pp. 135-138, Oct. 3, 1997.
Kiefer, L.L. et al., “Mutations in the Carboxyl Terminus of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors,”Biochemistry, vol. 36, pp. 2084-2090, 1997, published by American Chemical Society.
Fong, T. M. et al., “ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Reptors,”Biochemical and Biophysical Res. Comm., vol. 237, pp. 629-631, 1997, published by Academic Press.
Asagarasu, A. et al., “Synthesis of Dipeptide-Type Human Immunodeficiency Virus (HIV) Protease Inhibitors with a Binding Unit to GP120,”Chem. Pharm. Bull., vol. 46, No. 5, pp. 867-870, 1998, published by Pharmaceutical Society of Japan.
Rossi, M. et al., “A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo,”Endocrinology, vol. 139, No. 10, pp. 4428-4431, 1998, published by The Endocrine Society.
Hadley, M. E. et al., “The Proopiomelanocortin System,”Ann. N. Y. Acad. Sci., 885:1, pp. 1-21, 1999.
Smolnik, R. et al., “Brain Potentials and Attention after Acute and Subchronic Intranasal Administration of ACTH 4-10 and Desacetyl-α-MSH in Humans,”Neuroendocrinology, vol. 70, pp. 63-72, 1999, published by S. Karger AG, Basel.
Fehm, H. L. et al., “The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin4-10Decreases Body Fat in Humans,”J. Clin. Endocrinology&Metabolism, vol. 86, No. 3, pp. 1144-1148, 2001, published by the Endocrine Society.
Smith, R. A. et al., “Discovery and Parallel Synthesis of a New Class of Cathepsin K Inhibitors,”Bioorganic& Medicinal Chemistry Letters, vol. 11, pp. 2951-2954, 2001, published by Elsevier Science Ltd.
Shadiak, A. M. et al. “Intranasal Delivery of a Melanocortin for the Treatment of Sexual.Dysfunction,” Presentation at Fifth International Conference Exploring the Rapidly Developing Area of Nasal Drug Delivery, Mar. 21 and 22, Le Meridien Hotel, Piccadilly, London, United Kingdom.
Runti, C.: DeNardo, M.; Ulian F., “Fusaric Acid Derivatives and Analogues as Possible Antihypertensive Drugs,” II Farmaco Edizione Scientifica, vol. 36(4), pp. 260-268 (1981), published in Italy by the Society of Italian Pharmaceutical Science. This is an English-language document.
Cupps et al. (1998): STN International, CAPLUS database, Columbus (Ohio), Accession number 1998: 388504.
Aurrecoechea Natalia
Boyce Rustum S.
Chang Bryan
Chu Daniel
Smith Aaron
Chiron Corporation
Collier Steven W.
Friedrichsen Bernard P.
Harbin Alisa A.
LandOfFree
Substituted quinazolinone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted quinazolinone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinazolinone compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3607905